|
||||||||
![]() |
||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
The vector sequence has been compiled using the information from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced. |
|||||||||||||||||||||||||||||||||||||||||||||||||
![]() Download
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
pTagYFP-actin is a mammalian expression vector encoding TagYFP-actin fusion protein (see reporter description). The vector can be used for fluorescent labeling of
![]() | Stably transfected U-205 human osteosarcoma cells expressing TagYFP-tagged |
TagYFP codon usage is optimized for high expression in mammalian cells (humanized) [Haas et al., 1996]. Human cytoplasmic
pTagYFP-actin vector can be used as a source of TagYFP-actin hybrid sequence. The vector backbone contains unique restriction sites that permit its excision and further insertion into expression vector of choice.
Note: The plasmid DNA was isolated from dam+-methylated
The vector backbone contains immediate early promoter of cytomegalovirus (PCMV IE) for protein expression, SV40 origin for replication in mammalian cells expressing SV40 T-antigen, pUC origin of replication for propagation in
SV40 early promoter (PSV40) provides neomycin resistance gene (Neor) expression to select stably transfected eukaryotic cells using G418. Bacterial promoter (P) provides kanamycin resistance gene expression (Kanr) in
Expression in mammalian cells
pTagYFP-actin vector can be transfected into mammalian cells by any known transfection method. CMV promoter provides strong, constitutive expression of the TagYFP-actin fusion in eukaryotic cells. If required, stable transformants can be selected using G418 [Gorman, 1985].
Propagation in
Suitable host strains for propagation in
Location of features
PCMV IE: 1-589
Enhancer region: 59-465
TATA box: 554-560
Transcription start point: 583
Kozak consensus translation initiation site: 606-616
TagYFP
Start codon (ATG): 613-615
Last amino acid in TagYFP: 1327-1329
Beta-Actin: 1351-2478
Stop codon: 2476-2478
SV40 early mRNA polyadenylation signal
Polyadenylation signals: 2639-2644 & 2668-2673
mRNA 3' ends: 2677 & 2689
f1 single-strand DNA origin: 2736-3191
Bacterial promoter for expression of Kanr gene
-35 region: 3253-3258
-10 region: 3276-3281
Transcription start point: 3288
SV40 origin of replication: 3532-3667
SV40 early promoter
Enhancer (72-bp tandem repeats): 3365-3436 & 3437-3508
21-bp repeats: 3512-3532, 3533-3553 & 3555-3575
Early promoter element: 3588-3594
Major transcription start points: 3584, 3622, 3628 & 3633
Kanamycin/neomycin resistance gene
Neomycin phosphotransferase coding sequences:
Start codon (ATG): 3716-3718
Stop codon: 4508-4510
G->A mutation to remove Pst I site: 3898
C->A (Arg to Ser) mutation to remove BssH II site: 4244
Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal
Polyadenylation signals: 4746-4751 & 4759-4764
pUC plasmid replication origin: 5095-5738
Evrogen Fluorescent Protein Products (the Products) are intended for research use only. The Products are covered by Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License.
The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839, and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.
|
Copyright 2002-2011 Evrogen. All rights reserved. Evrogen JSC, 16/10 Miklukho-Maklaya str., Moscow, Russia, Tel +7(495)988-4084, Fax +7(495)988-4085, e-mail:evrogen@evrogen.com |